Close Menu

When the Bush administration came in and Todd Dickinson left his post as director of the US Patent and Trademark Office, there were approximately 10,000 outstanding gene-based patent applications. Early patents of this type tended to be full-length sequences; now, most focus on ESTs or SNPs. Since April, Dickinson hangs his shingle at the law firm Howrey Simon Arnold and White, where he’s a partner dealing with IP. GT’s Meredith Salisbury caught up with him to find out about guidelines, evaluations, and patent pooling.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.